Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $311,058.50 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 13,015 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $23.90, for a total transaction of $311,058.50. Following the sale, the insider directly owned 105,839 shares of the company’s stock, valued at $2,529,552.10. This represents a 10.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Down 3.4%

KMTS opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a fifty day moving average of $22.78 and a 200-day moving average of $22.52. The stock has a market cap of $1.47 billion, a PE ratio of -10.36 and a beta of 0.58. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. On average, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies in the fourth quarter valued at $31,000. Russell Investments Group Ltd. boosted its stake in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the period. Daiwa Securities Group Inc. bought a new stake in Kestra Medical Technologies in the 4th quarter worth $72,000. BNP Paribas Financial Markets boosted its holdings in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the last quarter.

Analyst Upgrades and Downgrades

KMTS has been the subject of several recent research reports. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. The Goldman Sachs Group lowered their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Finally, BTIG Research lifted their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.